Chemotherapy in combination with bevacizumab in breast cancer. Results of the observational study in daily clinical practice

In metastatic breast cancer (MBC) the combination of Bevacizumab (Avastin) and chemotherapy (CT) failed to demonstrate an increase in overall survival with a significant improvement of the objective response rate and progression-free survival (PFS) in randomized trials of the 3d phase. Nevertheless, observational studies in the daily clinical practice for the use of Bevacizumab in MBC continue in the world. We present the results of our own observational study, which goal is to assess the efficacy and tolerability of Bevacizumab in combination with CT in patients with HER/2-negative metastatic and locally advanced breast cancer. The study included 34 patients with breast cancer (6-locally advanced, 28-metastatic) at the age of 29 to 66 years (mean – 49.5). Bevacizumab was administered at a dose of 7.5 to 15 mg/kg every 3 weeks in combination with CT. In total, the patients received 294 doses of Bevacizumab (median – 10). All patients with locally advanced breast cancer were operated on after the treatment completion, a pathologic complete response was registered in 33.3%. In MBC, the objective response was registered in 46,4%, tumor growth control in 89.3%, median PFS – 10 months. Typical for Bevacizumab adverse events, such as hypertension, proteinuria, were moderate and were met respectively in 14.7% and in 5.9% cases. In 1 (2.9%) patient the treatment was complicated by deep vein thrombosis and PE due to disease progression. Conclusion. Bevacizumab in combination with CT in breast cancer treatment can achieve high rates of objective response and PFS independent of the treatment line

1. Miller K., Wang M., Gralow J. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N. Engl. J. Med., 2007, Vol. 357, No. 26, pp. 2666–76.

2. Gray R., Bhattacharya S., Bouden C. et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer, J. Clin. Oncol., 2009, Vol. 27, No. 30, pp. 4966–72.

3. Miles D.W., Chan A., Dirix L.Y. et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer, J. Clin. Oncol., 2010, Vol. 28, No. 20, pp. 3239–47.

4. Robert N. J., Dieras V., Glaspy J. et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer, J. Clin. Oncol., 2011, Vol. 29, No. 10, pp. 1252–60

5. Brufsky A.M., Hurvitz S., Perez E. et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer, J. Clin. Oncol., 2011, Vol. 29, No. 32, pp. 4286–93.

6. Brufsky A., Valero V., Tiangco B. et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial, Breast Cancer Res. Treat., 2012, Vol. 133, No. 3, pp. 1067–75.

7. Miles D.W., Dieras V., Cortes J., Duenne A.A., Yi J., O’Shaughnessy J. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients, Ann. Oncol., 2013, Vol. 24, No. 11, pp. 2773–80.

8. Lang I., Brodowicz T., Ryvo L. et al. Central European Cooperative Oncology Group. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial, Lancet Oncol., 2013, Vol. 14, No. 2, pp. 125–33.

9. Croom K. F., Dhillon S. Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer, Drugs, 2011, Vol. 71. No. 16, pp. 2213–29.

10. Bertucci F., Finetti P., Birnbaum D. Basal Breast Cancer: A Complex and Deadly Molecular Subtype, Curr. Mol. Med., 2012, Vol. 12, No. 1, pp. 96–110.

11. von Minckwitz G., Eidtmann H., Rezai M. et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer, N. Engl. J. Med., 2012, Vol. 366, No. 4, pp. 299–309.

12. von Minckwitz G., Untch M., Blohmer J.U. et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes, J. Clin. Oncol., 2012, Vol. 30, No. 15, pp. 1796–804.

13. Cortes J., Calvo V., Ramirez-Merino N., O’Shaughnessy J. et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis, Ann. Oncol., 2012, Vol. 23, No. 5, pp. 1130–7, Epub 2011 Oct 4.

14. Rossari J.R., Metzger-Filho O., Paesmans M. et al. Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence, J. Oncol., 2012: 417673, Epub 2012 Sep 12.

15. Lam S.W., de Groot S.M., Honkoop A.H. et al. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial, Eur. J. Cancer., 2014, Vol. 50, No. 18, pp. 3077–88.

16. von Minckwitz G., Puglisi F., Cortes J. et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial, Lancet Oncol., 2014, Vol. 15, No. 11, pp. 1269–78.

17. Delaloge S., Perol D., Courtinard C. et al.. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study, Ann. Oncol., 2016, Vol. 27, No. 9, pp. 1725–32.

18. Miles D., Cameron D., Bondarenko I., Manzyuk L. et al. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation, Eur. J. Cancer, 2017, No. 70, pp. 146–155.